Standout Papers

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s dise... 2020 2026 2022 2024249
  1. Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval (2020)
    Martin Tolar, Susan Abushakra et al. Alzheimer s Research & Therapy

Immediate Impact

7 from Science/Nature 72 standout
Sub-graph 1 of 21

Citing Papers

A natural experiment on the effect of herpes zoster vaccination on dementia
2025 StandoutNature
Biomarker Changes during 20 Years Preceding Alzheimer’s Disease
2024 Standout
2 intermediate papers

Works of Susan Abushakra being referenced

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
2020 Standout
CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT”
2016

Author Peers

Author Last Decade Papers Cites
Susan Abushakra 982 432 446 42 1.5k
Joyce Suhy 997 595 333 47 1.8k
Konstantina G. Yiannopoulou 631 251 377 29 1.5k
Marina Zvartau‐Hind 773 219 300 22 1.4k
Paul Ardayfio 867 428 321 31 1.6k
R. Anand 481 307 459 41 1.9k
Carlo Masullo 615 476 255 67 2.1k
Alette M. Wessels 952 673 307 46 1.8k
Keith M. Gregg 848 419 276 21 1.8k
Gary Tong 845 346 317 34 2.1k
Michael P. Murphy 967 133 311 51 2.1k

All Works

Loading papers...

Rankless by CCL
2026